Why the study?
Bariatric surgery reduces the progression of CKD to ESKD, but the risk of perioperative complications remains a concern.
Does chronic kidney disease increase the risk of 30-day perioperative complications and mortality in patients undergoing bariatric surgery?
Does chronic kidney disease increase the risk of 30-day perioperative complications and mortality in patients undergoing bariatric surgery?
Bariatric surgery is associated with low absolute rates of 30-day postoperative complications even in patients with advanced CKD, supporting its safety as a renoprotective intervention.
Low absolute mortality supports bariatric surgery consideration in advanced CKD; leaves open need for randomized confirmation.
Background: . Bariatric surgery reduces progression of CKD to ESKD, but the risk of perioperative complications remains a concern. Methods: The 24-month data spanning 2017-2018 were obtained from the Metabolic and Bariatric Surgery Quality Improvement Program (MBSAQIP) database and analyzed. Surgical complications were assessed on the basis of the length of hospital stay, mortality, reoperation, readmission, surgical site infection (SSI), and worsening of kidney function during the first 30 days after surgery. Results: <0.001) times more likely to die compared with those with normal kidney function. However, absolute mortality rates remained relatively low at 0.53% in those with stage 3b CKD. Furthermore, absolute mortality rates were <0.5% in those with stages 4 and 5 CKD, and these advanced CKD stages were not independently associated with an increased risk of early postoperative mortality. Conclusions: Increased severity of kidney disease was associated with increased complications after bariatric surgery. However, even for the population with advanced CKD, the absolute rates of postoperative complications were low. The mounting evidence for bariatric surgery as a renoprotective intervention in people with and without established kidney disease suggests that bariatric surgery should be considered a safe and effective option for patients with CKD.
No takes yet. Share an insight, caveat, or question.
Silveira et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: